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ABSTRACT
Introduction Clinical practice guidelines (CPGs) are 
intended to optimise patient care by recommending care 
pathways based on the best available research evidence 
and practice experience. Patient and public involvement 
(PPI) in healthcare is recommended based on the 
expectation that it will improve the quality and relevance 
of outcomes. There is no consensus on what constitutes 
meaningful and effective PPI in CPG. We will conduct a 
scoping review to identify and synthesise knowledge in 
four key areas: who have been the patients and public 
previously involved in CPG development, how were they 
recruited, at what stage in the CPG process were they 
involved and how were they involved. This knowledge 
will inform a general model of PPI in CPG to inform CPGs 
development.
Methods and analysis We will conduct a scoping review 
using the Methodology for Scoping Reviews refined by 
the Joanna Briggs Institute. Searches will be conducted 
in electronic databases (PubMed, Embase, CINAHL and 
PsycINFO). National standards for developing CPGs from 
Australia, UK, Canada and the USA will also be identified. 
A forward and backward citation search will be conducted 
on the included studies and national standards. Abstracts 
and full- text studies will be independently screened by two 
researchers. Extracted data will include study details, type 
of clinical guideline and the four key areas, which patients 
and public were involved, how were they recruited, at what 
stage were they included and how they were involved. 
Data will be narratively synthesised.
Ethics and dissemination As a scoping review, this study 
does not require ethics approval. We intend to disseminate 
the results through publication in a peer- reviewed journal 
and conference presentations. Furthermore, we will use 
the findings from our scoping review to inform future 
research to fill key evidence gaps identified by this review.
INTRODUCTION
Rationale
Clinical practice guidelines (CPGs) are 
intended to optimise patient care by recom-
mending care pathways for clinicians about 
the management of patients with specific 
conditions. They should be based on the 
best available research evidence and practice 
experience.1 Patient and public involvement 
(PPI) in healthcare, whether in research or 
to inform policy decisions, is recommended 
based on ethical principles and the expec-
tation that it will improve the relevance 
of the outcomes and quality of the deci-
sions.2 ‘Involvement’ is characterised as an 
active partnership between patients and/or 
members of the public and others.1
International guideline standards include 
PPI as a core principle for developing high- 
quality evidence- based CPGs.3 In Australia, 
the National Health and Medical Research 
Council (NHMRC) guideline standards 
recommend that the guideline development 
process should be multidisciplinary and 
include consumers.4 However, there is no 
consensus on who to include as consumers, 
for example, patients, caregivers, family 
members or consumer advocates, how many 
to include, at what stage in the develop-
ment process to include them or how best 
to include them.1 5 6 However, Canada7 and 
the UK6 are notable exceptions as both coun-
tries have published national standards that 
provide some answers to those questions.
The Canadian Task Force on Preven-
tive Health Care (CTFPHC) established to 
develop CPGs, published a protocol for incor-
porating patient experiences and views into 
the CPG development process.7 The patient 
engagement protocol provides guidance 
Strengths and limitations of this study
 ► This project will follow a robust design strategy 
that includes an established research framework, a 
search strategy and a selection process.
 ► The search strategy includes published primary 
studies in different databases with peer- reviewed 
literature, with no restrictions on study design or 
date of publication.
 ► This study will include published national standards 
for developing CPGs from Australia, UK, Canada and 
the USA but not books or grey literature.
 ► We acknowledge that we may not have included rel-
evant studies cited by the published national stan-
dards for guideline development in countries outside 
Australia, UK, USA and Canada.
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regarding who to include and when to include them. 
Acknowledging the limited research on PPI in guideline 
development, CTFPHC followed the recommendations 
of the Institute of Medicine (IOM)1 and the Appraisal of 
Guidelines for Research and Evaluation (AGREE) Collab-
oration.8 The IOM recommended including a patient 
with disease- specific experience and a patient advocate 
in the CPG development process.1 The AGREE Collab-
oration encouraged guideline developers to integrate 
patient experience and views into guideline development 
through formal consultation with patients and patient 
groups.8 Beginning in 2015, the CTFPHC patient engage-
ment protocol includes an arbitrary number of patients 
with disease- specific experience or their caregivers at 
three stages of guideline development: when deciding on 
which screening questions the guideline should address, 
rating the importance of test outcomes and, usability of 
the knowledge translation tools, for example, patient 
decision aids.7
Similarly, the National Institute for Health and Care 
Excellence (NICE) provides guidance, including clinical 
guidelines, for the UK National Health Service that focuses 
on the patient, service- user and carer.6 Their stated aim of 
PPI is to ensure that the experiences and perspectives of 
patients and public inform all NICE’s guidance products. 
That philosophy has been maintained since 2002 and 
strengthened in 2013 with the publication of a policy to 
guide PPI in NICE guidance products. How the CTFPH 
and NICE established the number of public and patients 
to include, the methods of recruitment, when and how 
to include PPI in the CPG development process is not 
explained and limits the application of both protocols.
A recent opinion article described PPI in guideline 
development in terms of when to involve patients and 
the public, how to recruit patients and the public, how 
to integrate personal experience with research evidence 
and what models of involvement are in practice.9 The 
authors provided no methodology for article selec-
tion or review of articles and no articles post-2015 were 
included. They suggested that despite international 
interest in incorporating PPI as a means of improving 
the quality of CPGs, there are no standardised method-
ologies to achieve meaningful PPI in guideline devel-
opment. It is not surprising then that 5 years after the 
IOM1 released standards for development of healthcare 
guidelines, only 8% of guideline developers in the USA 
required PPI in guideline development groups and only 
20% of guideline developers in the USA created patient- 
targeted guideline versions.10 This is despite research 
literature suggesting that PPI has a positive impact on 
guideline development through augmenting clinical 
care recommendations with patient- focused issues thus 
helping to realise the aim of the guidelines: to optimise 
patient care and outcomes.11 12 For example, involving 
infertile couples with professionals developing a multi-
disciplinary guideline on infertility broadened the scope 
of the guideline by including patient- identified clinical 
issues.12
Over a decade ago in Australia, the NHMRC suggested 
that a clinical guideline development panel may need 
to establish a separate consumer focus group to facili-
tate identification of all relevant consumer experiences, 
concerns and recommendations.4 Workshops for the 
members of the guideline development panels were also 
suggested as a way of bringing together multidisciplinary 
groups, including consumers, to determine the need for 
CPGs and discuss the methods to be used in their prepa-
ration. Evidence of this approach is scarce, but some 
research supports this approach as indicative of a feasible 
methodology for answering the PPI in guideline develop-
ment questions of who, when and how.11 13 14
First, as part of a multidisciplinary approach to develop 
a CPG on early- stage chronic kidney disease, peer- 
facilitated workshops involving patients with chronic 
kidney disease and their carers were convened to identify 
patient- focused topics and outcomes.13 These workshops 
operated in parallel with the guideline working group. 
The recommendations of the patient/carer workshops 
were provided to the guideline working group. Using 
a before- and- after comparison of the chronic kidney 
disease CPGs, this approach to PPI resulted in a CPG that 
was patient endorsed, augmented with consumer- focused 
issues and complemented by a plain English decision- 
making tool.13
Second, another research group conducted parallel 
guideline development groups to investigate the impact 
of PPI on guideline question formation for diagnosing 
dementia.14 One guideline group included patients, 
spouses, patient advocates and physicians, while the other 
involved physicians only. In line with previous findings, 
the CPG developed with PPI differed from the parallel 
guideline in that it included patient- relevant topics 
such as rate of disease progression and suggestions for 
dissemination of the guideline for patients and advo-
cates. Notably, the physician- only group ‘forgot’ to draft a 
plain- language version of the questions they proposed.14 
In both these approaches, PPI was limited to one or two 
stages of the guideline development process and those 
stages were arbitrarily determined by the researchers.13 14
Third, in another parallel study, guidelines for the 
treatment of irritable bowel syndrome were developed 
by guideline development groups with and without PPI.15 
Both guideline development groups had standardised 
methods for CPG development, and for data interpreta-
tion, however, group membership differed. One guideline 
group comprised physicians, mental health professionals 
and patients, their carers and patient advocates, while the 
other included physicians only. Again, the CPGs devel-
oped by the multidisciplinary group were considered 
more patient centric and inclusive of more psychosocial 
concerns than those from the physician- only group.
Governments, funding bodies and guideline developers 
worldwide seek to involve patients and the broader public 
in development of CPGs. However, there is no agreed 
model nor consistent methodology for meaningful PPI in 
guideline development. We will conduct a scoping review 
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to synthesise the literature that describes four key compo-
nents of meaningful PPI in guideline development: who 
have been the patients and public previously involved in 
CPG, how were they recruited, at what stage in the CPG 
process were they involved and how were they involved.
Objectives
We aim to systematically scope the literature on PPI in 
the development of CPGs and to identify and synthesise 
knowledge about who to include, how to recruit them, 
at what stage in the development process to include 
them and the methods of involvement. We anticipate 
this knowledge will inform a general model that can be 
adopted and adapted specifically for PPI in development 
of CPGs.
METHODS AND ANALYSIS
Scoping review
A scoping review is more appropriate than a systematic 
review in mapping the different concepts that describe 
involvement of patients and public in development of 
CPGs. Being broader than systematic reviews, scoping 
reviews clarify key concepts in the literature and identify 
knowledge gaps.16 They are considered to be hypothesis 
generating rather than hypothesis testing and have the 
potential to inform further research directions.16 The 
proposed scoping review will be conducted based on 
the methodological framework developed by Arksey and 
O’Malley17 and refined by the Joanna Briggs Institute 
(JBI).18
Identifying the research question
The primary research question has four components: who 
have been the patients and public previously involved in 
CPG, how were they recruited, at what stage in the CPG 
process were they involved and how were they involved. 
As scoping reviews are an iterative process, additional 
research questions may arise as we proceed.17
Identifying relevant studies
Based on preliminary searches in PubMed, a seminal article 
was located providing an overview of the current practices 
and future challenges of PPI in guideline development.9 
The overview paper discussed the four questions directly 
related to our interest in facilitating PPI in developing 
CPGs, but there was no methodology provided and no 
articles post-2015 were reviewed. Therefore, we extracted 
the references directly related to the four components of 
our research question to assist with keyword identification. 
We followed the JBI’s18 two- step search strategy, that is, 
first a limited search of PubMed, considered appropriate 
for this topic. The citations extracted from the overview 
paper9 then served as a validation set for this stage. The 
search was iteratively developed, in collaboration with a 
research information specialist, to ensure the validation 
set of key papers was found in the PubMed search. The 
validation set was analysed for key words and phrases, 
and a second- step search strategy was constructed. Search 
terms were deliberately broad so as not to unduly limit 
articles.19 The search strategy constructed for PubMed is 
shown in online supplemental appendix 1.
The initial second- step database search was conducted 
on 1 October 2019 in PubMed, Embase, CINAHL and 
PsycINFO. Our search strategy for published studies is 
international and does not exclude languages other than 
English. Our search of the grey literature of published 
national standards for guideline development is restricted 
to Australia and three countries that have a similar 
social and economic environment to Australia, that 
is, the UK, Canada and the USA. We will analyse those 
published national standards separately. Additionally, we 
will conduct a forward and backward citation search on 
included studies. We anticipate that combining interna-
tionally published research and health system content 
from similar health environments would inform a general 
model that can be adopted and adapted specifically for 
PPI in development of Australian clinical guidelines.
Study selection
Consistent with the JBI scoping review methodology,18 a 
two- part study selection process will be used: (1) a title 
and abstract review and (2) a full- text review. In the 
first step, two reviewers, one of the authors, EAB and a 
research assistant will independently review the titles 
and abstracts against the inclusion/exclusion criteria. 
Disputes will be resolved by consensus or referring to a 
third reviewer if required. Potentially included full texts 
will be independently reviewed by the same two reviewers. 
All studies excluded at the full- text screening stage will be 
recorded with reasons for exclusion.
We will include published primary studies that report 
PPI in CPG development specifically addressing the ques-
tions of who have been the patients and public involved 
in CPG, how were they recruited, at what stage in the CPG 
process were they involved and how were they involved. 
Reference lists of reviews, reporting some or all the study 
questions will be examined to verify all relevant primary 
studies have been included. No language or date restric-
tions will be applied.
We will exclude letters, opinion pieces, commentaries, 
reports and studies focused on PPI in health technology 
assessments. As we are aware of a registered systematic 
review protocol for a review of the evaluations of PPI 
models, we will exclude studies on that topic.20
Charting the data
Data will be extracted from the selected articles guided by 
our four scoping review components. Data extraction and 
analysis is anticipated to be finalised in August 2020. The 
first author, AB, and a research assistant have commenced 
piloting the data extraction form, but no data have been 
formally extracted. The same two researchers will extract 
data independently until 90% consensus is achieved. 
Then EAB will complete data extraction. All authors (RT, 
AMS and EAB) will contribute to data analysis.
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Ten included studies21 will be selected at random 
to pilot the data extraction form that will be modified 
if necessary, prior to its final use. Extracted data will 
include: author and date of publication, study title, study 
location, study design, population, type of clinical guide-
line, that is, for screening or therapeutic purposes, and 
organisation/s involved in developing the guideline and 
outcomes.
Outcomes will include which patients and public were 
involved in CPG development, how were they recruited, 
at what stage in the CPG process were they involved and 
how were they involved. We will report the most frequently 
used strategies and any qualitative and quantitative data 
arising from those strategies. If available, data arising 
from evaluation of those strategies will be reported. The 
patients and public involved in the CPG development 
process will be described as representing one of four 
groups: general public: citizens/community; screening 
population: the affected public but without disease- 
specific experience; treatment population/patients: the 
affected public with disease- specific experience; and 
advocates: representatives of interest groups and political 
organisations.22 Extracted data to describe recruitment 
of patients and public will include who made the initial 
contact and the method of contact, for example, email, 
telephone or website post. When were patients and public 
involved in the CPG development process will be speci-
fied, for example, guideline selection, topic or question 
identification, literature review, guideline writing process 
or draft guideline review. To adequately describe how 
patients and public were involved in the CPG develop-
ment process, we will extract the method of involvement, 
for example, focus group, survey or workshop and note 
the level of involvement, for example, consultation or 
codecision.
Consistent with the scoping review methodology of 
JBI18 and the scoping review questions, data extracted 
will be described using frequency counts of populations, 
methods of recruitment and involvement, and stage 
of involvement. For all four scoping review questions, 
descriptions of strategies reported as successful and 
unsuccessful will be subject to narrative data analysis.
Collating, summarising and reporting results
Screening results will be reported using Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
Extension for Scoping Reviews guidelines.23 Each research 
question will be reported separately. We will synthesise 
the study findings using narrative descriptions based on 
the themes that emerge from the extracted data.
Twitter Rae Thomas @rthomasEBP
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